6.9881
price down icon25.59%   -2.4119
 
loading
Immunitybio Inc stock is traded at $6.9881, with a volume of 60.14M. It is down -25.59% in the last 24 hours and down -39.44% over the past month. ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.
See More
Previous Close:
$9.40
Open:
$9.075
24h Volume:
60.14M
Relative Volume:
1.69
Market Cap:
$7.18B
Revenue:
$113.29M
Net Income/Loss:
$-351.47M
P/E Ratio:
-17.93
EPS:
-0.3898
Net Cash Flow:
$-309.19M
1W Performance:
-14.80%
1M Performance:
-39.44%
6M Performance:
+179.80%
1Y Performance:
+145.44%
1-Day Range:
Value
$6.54
$9.1499
1-Week Range:
Value
$6.54
$9.54
52-Week Range:
Value
$1.83
$12.43

Immunitybio Inc Stock (IBRX) Company Profile

Name
Name
Immunitybio Inc
Name
Phone
(844) 696-5235
Name
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Name
Employee
691
Name
Twitter
Name
Next Earnings Date
2024-11-06
Name
Latest SEC Filings
Name
IBRX's Discussions on Twitter

Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
IBRX icon
IBRX
Immunitybio Inc
6.9875 9.66B 113.29M -351.47M -309.19M -0.3898
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
450.21 114.63B 12.07B 3.95B 3.19B 15.33
REGN icon
REGN
Regeneron Pharmaceuticals Inc
737.73 77.87B 14.34B 4.50B 3.77B 41.56
ARGX icon
ARGX
Argen X Se Adr
676.77 42.32B 4.16B 1.29B 734.26M 19.58
ALNY icon
ALNY
Alnylam Pharmaceuticals Inc
304.83 40.67B 3.71B 313.75M 465.38M 2.2571
ONC icon
ONC
Beone Medicines Ltd Adr
275.01 30.50B 5.36B 287.73M 924.18M 2.5229

Immunitybio Inc Stock (IBRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-12-26 Resumed BTIG Research Buy
May-20-25 Upgrade Piper Sandler Neutral → Overweight
Mar-06-25 Initiated H.C. Wainwright Buy
Jan-10-25 Initiated BTIG Research Buy
May-12-23 Downgrade Piper Sandler Overweight → Neutral
Aug-03-22 Initiated Jefferies Buy
View All

Immunitybio Inc Stock (IBRX) Latest News

pulisher
12:33 PM

ImmunityBio (IBRX) Soars 11% as Asian Expansion Looms - Insider Monkey

12:33 PM
pulisher
Mar 23, 2026

IBRX Stock Rises Premarket: Anktiva Moves Into Pre-Surgery Pancreatic Cancer Combo Trial With Bristol Myers Drug - Stocktwits

Mar 23, 2026
pulisher
Mar 23, 2026

10 Stocks to Watch Today: QXO, ImmunityBio, PayPay, and More - Insider Monkey

Mar 23, 2026
pulisher
Mar 23, 2026

ImmunityBio (NASDAQ:IBRX) Shares Up 11%Here's What Happened - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Why ImmunityBio Stock Is Up More Than 11% Today - AOL.com

Mar 23, 2026
pulisher
Mar 23, 2026

Why ImmunityBio Stock Is Up More Than 11% Today - The Motley Fool

Mar 23, 2026
pulisher
Mar 23, 2026

ImmunityBio’s Asia Expansion: Macau Greenlights Anktiva for Bladder Cancer - StocksToTrade

Mar 23, 2026
pulisher
Mar 23, 2026

ImmunityBio (IBRX) Announces NCCN Update Clinical Practice Guidelines to Include ANKTIVA for Papillary-Only NMIBC - Insider Monkey

Mar 23, 2026
pulisher
Mar 23, 2026

ImmunityBio Receives Critical Approvals, Sees Significant Stock Gains - timothysykes.com

Mar 23, 2026
pulisher
Mar 23, 2026

ImmunityBio's (IBRX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat

Mar 23, 2026
pulisher
Mar 23, 2026

Can Anktiva's Label Expansion Unlock the Next Growth Phase for IBRX? - Yahoo Finance

Mar 23, 2026
pulisher
Mar 22, 2026

ImmunityBio Inc stock surges on promising Phase 3 cancer vaccine data amid biotech rally - AD HOC NEWS

Mar 22, 2026
pulisher
Mar 22, 2026

ImmunityBio (IBRX) climbs 7.3% as firm nears development of 'world bank of NK cells' - MSN

Mar 22, 2026
pulisher
Mar 22, 2026

ImmunityBio, Inc. (NASDAQ:IBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Mar 22, 2026
pulisher
Mar 21, 2026

How Investors May Respond To ImmunityBio (IBRX) Securing First Asian Approval For ANKTIVA Via Macau Pathway - Yahoo Finance

Mar 21, 2026
pulisher
Mar 21, 2026

Jim Cramer on ImmunityBio: “That Stock Is Part of the Magical Thinking Era” - Insider Monkey

Mar 21, 2026
pulisher
Mar 21, 2026

Promising Biotech Stocks To Keep An Eye OnMarch 21st - MarketBeat

Mar 21, 2026
pulisher
Mar 21, 2026

IBRX Stock Set To Snap 2 Weeks In Red: Anktiva Joins Global Blockbusters On Macau Drug List - Stocktwits

Mar 21, 2026
pulisher
Mar 21, 2026

BTIG sees upside in ImmunityBio, Inc. (IBRX), cites strong 2026 ANKTIVA sales growth - MSN

Mar 21, 2026
pulisher
Mar 21, 2026

ImmunityBio Gains First Asian ANKTIVA Nod As Cell Therapy Story Builds - Sahm

Mar 21, 2026
pulisher
Mar 20, 2026

BTIG Sees Upside in ImmunityBio, Inc. (IBRX), Cites Strong 2026 ANKTIVA Sales Growth - Insider Monkey

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Down 4%Should You Sell? - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio Sees Unusually High Options Volume (NASDAQ:IBRX) - MarketBeat

Mar 20, 2026
pulisher
Mar 20, 2026

First ANKTIVA approval in Asia gives bladder cancer drug a Macau entry - Stock Titan

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives approval for ANKTIVA in Macau for bladder cancer - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives Macau approval for bladder cancer drug By Investing.com - Investing.com India

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio (IBRX) Is Up 12.8% After NCCN Expands ANKTIVA Bladder Cancer Guideline InclusionWhat's Changed - simplywall.st

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio receives Macau approval for bladder cancer drug - Investing.com

Mar 20, 2026
pulisher
Mar 20, 2026

ImmunityBio announces approval in Macau SAR, China for Anktiva - marketscreener.com

Mar 20, 2026
pulisher
Mar 20, 2026

Immunitybio Announces Approval In Macau SAR, China For Anktiva - TradingView

Mar 20, 2026
pulisher
Mar 20, 2026

IBRX Stock Rises Premarket As Founder Flags Early Anktiva Immune Data — Macau Nod Fuels Bull Case - Stocktwits

Mar 20, 2026
pulisher
Mar 20, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 20, 2026
pulisher
Mar 19, 2026

ImmunityBio (NASDAQ:IBRX) Shares Up 3%Should You Buy? - MarketBeat

Mar 19, 2026
pulisher
Mar 19, 2026

ImmunityBio gains as NCCN guidelines include new Anktiva indication - MSN

Mar 19, 2026
pulisher
Mar 19, 2026

After years of delays, new deadline looms in 2028 for drug manufacturing plant in Dunkirk - Buffalo News

Mar 19, 2026
pulisher
Mar 19, 2026

Assessing ImmunityBio (IBRX) Valuation After NCCN ANKTIVA Update And NK Cell Therapy Progress - simplywall.st

Mar 19, 2026
pulisher
Mar 18, 2026

ImmunityBio Inc Trade Ideas — SWB:26CA - TradingView

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (IBRX) Clinical Trial for Lymphona Drug Follows $505M Convertible Note Change - MSN

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (NASDAQ:IBRX) Stock Price Up 4.3%Here's Why - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio (IBRX) Resubmits sBLA to FDA for ANKTIVA in Papillary Bladder Cancer - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio Stock Jumps on Big Cancer Breakthrough - TipRanks

Mar 18, 2026
pulisher
Mar 18, 2026

5 Most Buzzing Stocks to Buy with the Highest Upside Potential - Insider Monkey

Mar 18, 2026
pulisher
Mar 18, 2026

ImmunityBio Highlights ANKTIVA Surge, FDA Papillary Filing and Key 2026 Milestones at Conference - MarketBeat

Mar 18, 2026
pulisher
Mar 18, 2026

Heights Capital Management Inc. Purchases New Position in ImmunityBio, Inc. $IBRX - MarketBeat

Mar 18, 2026
pulisher
Mar 17, 2026

IBRX Stock Rises After NCCN Guideline Update Expands ANKTIVA’s UseRetail Expects Sales To Surge - Stocktwits

Mar 17, 2026
pulisher
Mar 17, 2026

Is 28.9% Fall In ImmunityBio (IBRX) Stock A Buying Opportunity? - Trefis

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio's Anktiva Could See More Upside: My Updated Thoughts On Expansion - Seeking Alpha

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Stock To $6? - Trefis

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Stock Jumps As New Bladder Cancer Guideline Boosts Anktiva Use - Benzinga

Mar 17, 2026
pulisher
Mar 17, 2026

NCCN Guideline Expansion Puts ANKTIVA And ImmunityBio Growth In Focus - Yahoo Finance

Mar 17, 2026
pulisher
Mar 17, 2026

ImmunityBio Announces NCCN® Clinical Practice Guidelines in Oncology Have Been Updated to Include AN - PharmiWeb.com

Mar 17, 2026

Immunitybio Inc Stock (IBRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Immunitybio Inc Stock (IBRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Selecky Christobel
Director
Feb 23 '26
Option Exercise
2.98
25,000
74,500
25,000
Selecky Christobel
Director
Feb 23 '26
Sale
10.00
25,000
250,000
0
Sachs David C.
Chief Financial Officer
Feb 22 '26
Option Exercise
0.00
40,650
0
320,825
SOON-SHIONG PATRICK
See remarks
Feb 22 '26
Option Exercise
0.00
114,329
0
29,816,081
LAUER REGAN J
Chief Accounting Officer
Feb 22 '26
Option Exercise
0.00
4,065
0
117,548
Adcock Richard
CEO & President
Feb 22 '26
Option Exercise
0.00
152,439
0
637,904
Simon Barry J.
Director
Feb 22 '26
Option Exercise
0.00
15,243
0
3,096,847
Simon Barry J.
Director
Feb 23 '26
Sale
10.25
165,000
1,691,102
2,925,821
Simon Barry J.
Director
Feb 20 '26
Sale
9.25
10,000
92,500
3,081,604
$27.00
price down icon 3.11%
$45.80
price up icon 0.40%
$52.10
price up icon 0.96%
$87.53
price down icon 1.01%
$141.04
price down icon 2.54%
ONC ONC
$275.51
price up icon 0.47%
Cap:     |  Volume (24h):